You are here: Industry Insights > ZERBAXA

News List

Merck secures FDA expanded indication for Zerbaxa pharmaceutical-technology
June 05, 2019
The US Food and Drug Administration (FDA) has approved Merck’s antibiotic Zerbaxa to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and above.
Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia drugs
June 05, 2019
Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia.
FDA Approves Zerbaxa (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) drugs
June 04, 2019
FDA Approves Zerbaxa (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP).
MSD to file antibiotic Zerbaxa for pneumonia pharmatimes
September 13, 2018
MSD is gearing up to file antibiotic Zerbaxa on both sides of the Atlantic for certain forms of pneumonia on the success of a late-stage trial backing its safety and efficacy.
Zerbaxa Meets Primary Endpoints americanpharmaceuticalreview
September 12, 2018
Merck announced the pivotal Phase 3 clinical study evaluating the company’s antibiotic Zerbaxa (ceftolozane and tazobactam) at an investigational dose for the treatment of adult patients with either ventilated hospital-acquired bacterial pneumonia (HABP)